These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 7965263

  • 1. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure.
    Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, DeKock M, LeJemtel T.
    J Hypertens Suppl; 1994 Jul; 12(2):S31-5. PubMed ID: 7965263
    [Abstract] [Full Text] [Related]

  • 2. Blockade of the renin-angiotensin system in heart failure in conscious dogs.
    Murakami M, Suzuki H, Naitoh M, Matsumoto A, Kageyama Y, Tsujimoto G, Saruta T.
    J Hypertens; 1995 Dec; 13(12 Pt 1):1405-12. PubMed ID: 8866902
    [Abstract] [Full Text] [Related]

  • 3. Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist.
    Niederberger M, Aubert JF, Nussberger J, Brunner HR, Waeber B.
    J Hypertens; 1995 Apr; 13(4):439-45. PubMed ID: 7629405
    [Abstract] [Full Text] [Related]

  • 4. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C, Cotter G, Reisin L, Bertel O, Kobrin I, Guyene TT, Kiowski W.
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [Abstract] [Full Text] [Related]

  • 5. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
    Bauer IH, Reams GP, Wu Z, Lau-Sieckman A.
    J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
    [Abstract] [Full Text] [Related]

  • 6. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, Kiowski W, Marks DS, Alegria E, Dukát A, Lenz K, Arens HA.
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [Abstract] [Full Text] [Related]

  • 7. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.
    Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE.
    J Hypertens Suppl; 1994 Jul; 12(2):S37-42. PubMed ID: 7965264
    [Abstract] [Full Text] [Related]

  • 8. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE.
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [Abstract] [Full Text] [Related]

  • 9. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
    Hülsmann M, Stanek B, Frey B, Berger R, Rödler S, Siegel A, Hartter E, Schuller M, Ogris E, Pacher R.
    J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
    [Abstract] [Full Text] [Related]

  • 10. Discovery of losartan, the first angiotensin II receptor antagonist.
    Timmermans PB, Duncia JV, Carini DJ, Chiu AT, Wong PC, Wexler RR, Smith RD.
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S3-18. PubMed ID: 8583479
    [Abstract] [Full Text] [Related]

  • 11. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM, Goldberg AI.
    Blood Press Suppl; 1996 Nov; 2():82-6. PubMed ID: 8913546
    [Abstract] [Full Text] [Related]

  • 12. The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.
    Lacourcière Y.
    Can J Cardiol; 1995 Aug; 11 Suppl F():45F-48F. PubMed ID: 7664218
    [Abstract] [Full Text] [Related]

  • 13. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.
    Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M.
    Circulation; 1993 Oct; 88(4 Pt 1):1602-9. PubMed ID: 8403307
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II antagonism: a new avenue of hypertension management.
    Gavras H.
    Blood Press Suppl; 1997 Oct; 1():42-6. PubMed ID: 9285108
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers.
    Duranteau J, Pussard E, Berdeaux A, Giudicelli JF.
    Br J Clin Pharmacol; 1995 Nov; 40(5):431-8. PubMed ID: 8703646
    [Abstract] [Full Text] [Related]

  • 17. The advantages of angiotensin II antagonism.
    Burnier M, Waeber B, Brunner HR.
    J Hypertens Suppl; 1994 Jul; 12(2):S7-15. PubMed ID: 7965267
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 19. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V, Seferovic P, Dodic S, Krotin M, Neskovic A, Dickstein K, de Voogd H, Böcker C, Ziegler D, Godes M, Nakov R, Essers H, Verboom C, Hocher B.
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
    Dickstein K, Chang P, Willenheimer R, Haunsø S, Remes J, Hall C, Kjekshus J.
    J Am Coll Cardiol; 1995 Aug; 26(2):438-45. PubMed ID: 7608448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.